Results 1 to 10 of about 57,261 (311)
Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma [PDF]
Iranian Journal of Medical Sciences, 2023 Background: Pancreatic cancer is a malignancy with high mortality due to the difficulties in early detection. We investigated and compared the diagnostic and prognostic performance of several blood biomarkers, including microRNA-25 (miR-25), carbohydrate
Yan Gong +5 more
doaj +1 more source
RETRACTED: Parallel Encryption With Digit Arithmetic Of Covertext Model Using Duplicated Covertext
Inspiration, 2022 Steganography is the art and science of writing hidden messages or hiding messages in such a way that, apart from the sender and the recipient, no one knows or is aware that there is a secret message (it does not appear that there is a hidden message ...
Hari Murti +3 more
doaj +1 more source
Cells, 2020 Increased metabolic acid production and upregulation of net acid extrusion render pH homeostasis profoundly dysregulated in many cancers. Plasma membrane activity of vacuolar H+ ATPases (V-ATPases) has been implicated in acid extrusion and invasiveness ...
Mette Flinck +7 more
doaj +1 more source
Interrelationship between miRNA and splicing factors in pancreatic ductal adenocarcinoma
Epigenetics, 2022 Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers because of diagnosis at late stage and inherent/acquired chemoresistance.
I Gede Putu Supadmanaba +8 more
doaj +1 more source
DUSP2 regulates extracellular vesicle-VEGF-C secretion and pancreatic cancer early dissemination
Journal of Extracellular Vesicles, 2020 Early dissemination is a unique characteristic and a detrimental process of pancreatic ductal adenocarcinoma (PDAC); however, the underlying mechanism remains largely unknown.
Chu-An Wang +10 more
doaj +1 more source
Autoimmunity, 2022 Background The hsa_circRNA_103809 (circ_0072088) has been an emerging tumour regulator in human cancers, and is identified as one most aberrantly expressed circRNA in patients with pancreatic ductal adenocarcinoma (PDAC).
Hui Sun, Fang Liu, Hongqing Zhang
doaj +1 more source
Cancer Biology & Medicine, 2023 Objective: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy. CD8+ T cells, cancer stem cells (CSCs), and tumor budding (TB) have been significantly correlated with the outcome of patients with PDAC, but the correlations have been ...
Tianxing Zhou +11 more
doaj +1 more source
Metabolism remodeling in pancreatic ductal adenocarcinoma
Cell Stress, 2019 Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second leading cause of death of patients with malignant cancers by 2030. Current options of PDAC treatment are limited and the five-year survival rate is less than 8%, leading to an ...
Jin-Tao Li +3 more
doaj +1 more source
International Journal of Hyperthermia, 2021 Purpose This study aimed to compare the survival benefits between high-intensity focused ultrasound (HIFU) combined with chemotherapy and chemotherapy alone in patients with unresectable pancreatic ductal adenocarcinoma (PDAC).
Jing Guo +4 more
doaj +1 more source
Targeting RAS in Pancreatic Ductal Adenocarcinoma: From Molecular Breakthroughs to Phase III Clinical Validation and Beyond [PDF]
Journal of Clinical QuestionPancreatic ductal adenocarcinoma (PDAC) is driven by oncogenic RAS signaling in more than 90% of tumors, most commonly through KRAS mutations, yet direct pharmacologic inhibition of this dominant oncogenic driver remained elusive for decades.
En Wang +6 more
doaj +1 more source